# Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

> **NCT05502341** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 689 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Bictegravir
- **DRUG:** Lenacapavir
- **DRUG:** BIC/LEN FDC
- **DRUG:** Stable Baseline Regimen

## Key facts

- **NCT ID:** NCT05502341
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-16
- **Primary completion:** 2025-09-29
- **Final completion:** 2028-07
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05502341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05502341, "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05502341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*